Can Sunergos Innovations address the research-funding gap in the north of the UK?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can Sunergos Innovations address the research-funding gap in the north of the UK?
Released on: March 03, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Sunergos Innovations is the commercialisation arm of Edinburgh University and NHS Lothian.
  • Summary
  • Transcript
  • Participants
  • Company
Sunergos Innovations is the commercialisation arm of Edinburgh University and NHS Lothian. Mike Capabaldi, CEO of Sunergos, discusses the current drive to expand their remit across the north of the UK.
Sunergos Innovations is the commercialisation arm of Edinburgh University and NHS Lothian. Mike Capabaldi, CEO of Sunergos, discusses the current drive to expand their remit across the north of the UK.
Mike has held senior roles in the pharmaceutical and life sciences industry since 1982, both in the UK and the USA. Previous large companies included Ciba Geigy, SmithKline & French and Amersham International where he headed up the Drug Development Services in the USA – later becoming an Executive Vice-President in Nycomed Amersham’s healthcare division. For the last 18 years, Mike has worked in the biotech/technology sector serving as executive director on the Boards of both publically listed and private companies including Core Group plc, Oxford Asymmetry plc, Mindweavers plc, Synaptica Ltd, Scancell plc, Hunter-Fleming Ltd and CMP Therapeutics Ltd (in the latter four companies as CEO). Mike is also currently a non-executive director of Stealthyx Therapeutics, Roslin Cells and Synaptica. He joined Edinburgh BioQuarter as Director in 2010 before founding Sunergos Innovations in October 2015.
Our Company Creation executives identify and develop novel scientific concepts and technologies from academics and clinicians, working together to exemplify their intellectual property and develop business plans to ensure proposals are ‘investor ready’. With extensive knowledge of industry, our team knows what the market wants and can deliver commercial proposals that are attractive to investors. In the past five years we’ve spun out more than ten new businesses, including i2eye Diagnostics Ltd, creators of the world’s first visual field analyser for children and vulnerable patient groups and Edinburgh Molecular Imaging which is developing a pioneering Optical Molecular Imaging technology with the potential to address unmet needs in the diagnosis and monitoring of several major diseases. We established Corticrine as a special purpose company to develop and finance an early stage drug (Xanamem™) for Alzheimer’s disease which had been funded by the Wellcome Trust. The company was merged with an Australian-listed biotech company which has raised over A$12m to complete Phase II development of Xanamem™. We have also launched a specialist Contract Research Organisation, Aquila BioMedical, focused on immunology and neuroscience.